Nicox Ausblick?
eröffnet am 15.06.21 09:16:26 von
neuester Beitrag 05.12.22 15:18:30 von
neuester Beitrag 05.12.22 15:18:30 von
Beiträge: 2
ID: 1.349.058
ID: 1.349.058
Aufrufe heute: 0
Gesamt: 141
Gesamt: 141
Aktive User: 0
ISIN: FR0013018124 · WKN: A143G8
0,3783
EUR
-0,26 %
-0,0010 EUR
Letzter Kurs 15.05.24 Lang & Schwarz
Neuigkeiten
06.05.24 · globenewswire |
02.05.24 · globenewswire |
24.04.24 · globenewswire |
22.04.24 · globenewswire |
09.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
55,25 | +513,89 | |
0,6400 | +68,42 | |
0,5500 | +52,78 | |
5,0900 | +33,60 | |
1,0000 | +33,33 |
Wertpapier | Kurs | Perf. % |
---|---|---|
2,1100 | -15,60 | |
1,3500 | -25,82 | |
0,5163 | -26,04 | |
0,7800 | -29,73 | |
2.849,50 | -83,34 |
Beitrag zu dieser Diskussion schreiben
Antwort auf Beitrag Nr.: 68.509.260 von ninebreak am 15.06.21 09:16:26Gibt zumindest noch Leute, die 10 Mio. in die Bude investieren
https://www.edisongroup.com/company/nicox/
Investment summary
Nicox announced a €10m private placement equity financing transaction, resulting in €8.9m in net proceeds. With the company extending the interest-only payment period of its existing Kreos Capital debt by six months (to January 2024), it has extended its estimated cash runway (based on the development of NCX-470 alone) to mid-May 2024, from mid-November 2023, previously. Altogether, Nicox issued 6.849m shares at an offering price of €1.46 per share (a 14% discount to the 21 November closing price) to Armistice Capital Master Fund, a healthcare and consumer sector focused hedge fund registered in the Cayman Islands. Nicox also affirmed that it now expects to complete Denali, the second NCX-470 Phase III study, in 2025, consistent with our existing estimates, although additional capital will be required. Our rNPV of €190.4m is unchanged, but our equity value per basic share is now €4.10 (vs €4.52 previously) given the additional shares outstanding.
Industry outlook
In addition to its IOP-lowering activity, Nicox is investigating whether NCX-470 can provide improvements to retinal perfusion, which may provide an additional protective mechanism for glaucoma treatment. Nicox had €25.6m gross cash at 30 September 2022 and has guided that it is financed into Q423, based on the development of NCX-470 alone.
Kohle noch da, bis Ende 2023
Setze die mal auf die WL.
😎
https://www.edisongroup.com/company/nicox/
Investment summary
Nicox announced a €10m private placement equity financing transaction, resulting in €8.9m in net proceeds. With the company extending the interest-only payment period of its existing Kreos Capital debt by six months (to January 2024), it has extended its estimated cash runway (based on the development of NCX-470 alone) to mid-May 2024, from mid-November 2023, previously. Altogether, Nicox issued 6.849m shares at an offering price of €1.46 per share (a 14% discount to the 21 November closing price) to Armistice Capital Master Fund, a healthcare and consumer sector focused hedge fund registered in the Cayman Islands. Nicox also affirmed that it now expects to complete Denali, the second NCX-470 Phase III study, in 2025, consistent with our existing estimates, although additional capital will be required. Our rNPV of €190.4m is unchanged, but our equity value per basic share is now €4.10 (vs €4.52 previously) given the additional shares outstanding.
Industry outlook
In addition to its IOP-lowering activity, Nicox is investigating whether NCX-470 can provide improvements to retinal perfusion, which may provide an additional protective mechanism for glaucoma treatment. Nicox had €25.6m gross cash at 30 September 2022 and has guided that it is financed into Q423, based on the development of NCX-470 alone.
Kohle noch da, bis Ende 2023
Setze die mal auf die WL.
😎
Hallo zusammen,
ist die Aktie tot oder denkt ihr, dass sich noch was tut und es mal wieder gen Norden geht?
ist die Aktie tot oder denkt ihr, dass sich noch was tut und es mal wieder gen Norden geht?
DurchsuchenBeitrag schreiben
06.05.24 · globenewswire · Nicox |
02.05.24 · globenewswire · Nicox |
24.04.24 · globenewswire · Nicox |
22.04.24 · globenewswire · Nicox |
09.04.24 · globenewswire · Nicox |
02.04.24 · globenewswire · Nicox |
22.03.24 · globenewswire · Nicox |
20.03.24 · globenewswire · Nicox |
13.03.24 · globenewswire · Nicox |
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting 05.03.24 · globenewswire · Nicox |